Meet ABL at Phacilitate Cell & Gene Therapy World

Washington, D.C. – January 7, 2016 – Meet ABL at Phacilitate Cell & Gene Therapy World in DC Jan 25-27 – Dr. Andy Macintyre Chairing Cancer Immunotherapy Diagnostic Session

ABL will be attending the Phacilitate Cell & Gene Therapy World conference at the Grand Hyatt in Washington, DC from January 25-27. Stop by our booth (#210) to talk about ABL’s biomanufacturing andresearch services. We are based in Rockville, Maryland and would be pleased to host any out of town visitors who would like to tour our facililty on their trip.

On January 26th, ABL’s Director of Immunobiology Dr. Andy Macintyre will chair Focus session 2 – Diagnostics to Guide Cancer Immunotherapy, followed by a discussion by the panel on Standardization and Harmonization in Therapies/CDx Adoption. The panel will discuss the following:

Challenges of standardizing companion diagnostics development when there are multiple drugs in the same class. Tackling the reality of a convergence of multiple drugs, multiple tests, and multiple indications for the same analyte.
Focusing on real-life uncertainties the healthcare community will face when a number of new PD-L1 and PD-1 inhibitors come to market, each with their own companion tests. What are the differences in analytical validation on the patient?
Critical appraisal of the research environment related to issues of immunotherapy pricing and companion diagnostics
We look forward to discussing your vaccine or therapeutic and how ABL may be able to help you reach your product development goals.

About ABL, Inc.

ABL, Inc. is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including the U.S. Government, biopharmaceutical companies and academic entities. Notable contract manufacturing services include process and assay development, cGMP biologics manufacturing of bulk drug substance, cGMP aseptic fill and finish of drug product, and QC analytics in the U.S. and Europe.  ABL also maintains U.S. and European immunological and molecular laboratories to support preclinical and GCLP clinical sample processing and testing. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally.

For more information visit www.ablinc.com or email us.